Last reviewed · How we verify
Flu-Tone (GINKGO)
At a glance
| Generic name | GINKGO |
|---|---|
| Sponsor | Energetix Corporation |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- flu-like symptoms
Common side effects
Key clinical trials
- A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment (PHASE4)
- Ginkgo Active App-Based Exercise Training (NA)
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin (NA)
- A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI (PHASE2)
- Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo (NA)
- Modifiable Risk Factors for Non-traumatic Subconjunctival Hemorrhage
- Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flu-Tone CI brief — competitive landscape report
- Flu-Tone updates RSS · CI watch RSS
- Energetix Corporation portfolio CI